Baird Maintains Outperform on Contineum Therapeutics, Lowers Price Target to $19

Benzinga Newsdesk www.benzinga.com Negative 94.4%

Neg 94.4% Neu 0% Pos 0%

Baird analyst Joel Beatty maintains Contineum Therapeutics (NASDAQ:CTNM) with a Outperform and lowers the price target from $20 to $19.